Vertex drug successfully reduced kidney disease marker in late-stage trial

Also: Leucovorin lacks evidence to use as autism treatment ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

March 10, 2026 Check out STAT+

Sponsored By

Sarah Silbiger/Getty Images/STAT Leucovorin lacks evidence to use as autism treatment, FDA says The FDA action represents a retreat from top officials' earlier insistence that leucovorin could benefit "hundreds of thousands" of children with autism. By O. Rose Broderick STAT+ | BioNTech founders to depart, form new mRNA-focused company Ugur Sahin and Özlem Türeci, who are married, founded the German biotech in 2008. It will continue developing medicines, with a focus on oncology. By Andrew Joseph STAT+ | Novo Nordisk is warned by the FDA for failing to report side effects tied to GLP-1 drugs This is the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices, placing the drugmaker on the defensive. By Ed Silverman Adobe STAT+ | Vertex says its drug successfully reduced marker of kidney disease in late-stage trial The biotech company is in a three-way race with Otsuka and Vera Therapeutics to treat the condition, called IgA nephropathy. By Jason Mast Health AI startup to benefit from $1 billion funding round for Yann LeCun's AMI Yann LeCun's Advanced Machine Intelligence raised $1 billion. STAT's Mario Aguilar breaks down the connection to health AI company Nabla. By Mario Aguilar STAT+ | Large drugmakers are developing fewer antibiotics, analysis finds The number of potential antimicrobial treatments being developed by the world's largest drugmakers nosedived by 35% — from 92 to 60. By Ed Silverman Mark Humphrey/AP Removing race from kidney function algorithm helped more Black patients access transplants A long-used medical test underestimated the severity of kidney disease in Black patients. New study says with the bias removed, transplant rates are up. By Anil Oza STAT+ | Opinion: The Himsification of medicine Hims has created a new mode of medicine, in which patients are consumers racing to buy into products and practices that feel aspirational and cutting-edge By Vishal Khetpal

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser